Cargando…

Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways

Since BRCA1 associated breast cancers are frequently classified as hormone receptor negative or even triple negative, the application of endocrine therapies is rather limited in these patients. Like hormone receptors that bind to estrogen or progesterone, thyroid hormone receptors (TRs) are members...

Descripción completa

Detalles Bibliográficos
Autores principales: Heublein, Sabine, Mayr, Doris, Meindl, Alfons, Angele, Martin, Gallwas, Julia, Jeschke, Udo, Ditsch, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451081/
https://www.ncbi.nlm.nih.gov/pubmed/26029931
http://dx.doi.org/10.1371/journal.pone.0127072
_version_ 1782374094162886656
author Heublein, Sabine
Mayr, Doris
Meindl, Alfons
Angele, Martin
Gallwas, Julia
Jeschke, Udo
Ditsch, Nina
author_facet Heublein, Sabine
Mayr, Doris
Meindl, Alfons
Angele, Martin
Gallwas, Julia
Jeschke, Udo
Ditsch, Nina
author_sort Heublein, Sabine
collection PubMed
description Since BRCA1 associated breast cancers are frequently classified as hormone receptor negative or even triple negative, the application of endocrine therapies is rather limited in these patients. Like hormone receptors that bind to estrogen or progesterone, thyroid hormone receptors (TRs) are members of the nuclear hormone receptor superfamily. TRs might be interesting biomarkers - especially in the absence of classical hormone receptors. The current study aimed to investigate whether TRs may be specifically expressed in BRCA1 associated cancer cases and whether they are of prognostic significance in these patients as compared to sporadic breast cancer cases. This study analyzed TRα and TRβ immunopositivity in BRCA1 associated (n = 38) and sporadic breast cancer (n = 86). Further, TRs were studied in MCF7 (BRCA1 wildtype) and HCC3153 (BRCA1 mutated) cells. TRβ positivity rate was significantly higher in BRCA1 associated as compared to sporadic breast cancers (p = 0.001). The latter observation remained to be significant when cases that had been matched for clinicopathological criteria were compared (p = 0.037). Regarding BRCA1 associated breast cancer cases TRβ positivity turned out to be a positive prognostic factor for five-year (p = 0.007) and overall survival (p = 0.026) while TRα positivity predicted reduced five-year survival (p = 0.030). Activation of TRβ resulted in down-modulation of CTNNB1 while TRα inhibition reduced cell viability in HCC3153. However, only BRCA1 wildtype MCF7 cells were capable of rapidly degrading TRα1 in response to T3 stimulation. Significantly, this study identified TRβ to be up-regulated in BRCA1 associated breast cancer and revealed TRs to be associated with patients’ prognosis. TRs were also found to be expressed in triple negative BRCA1 associated breast cancer. Further studies need to be done in order to evaluate whether TRs may become interesting targets of endocrine therapeutic approaches, especially when tumors are triple-negative.
format Online
Article
Text
id pubmed-4451081
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44510812015-06-09 Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways Heublein, Sabine Mayr, Doris Meindl, Alfons Angele, Martin Gallwas, Julia Jeschke, Udo Ditsch, Nina PLoS One Research Article Since BRCA1 associated breast cancers are frequently classified as hormone receptor negative or even triple negative, the application of endocrine therapies is rather limited in these patients. Like hormone receptors that bind to estrogen or progesterone, thyroid hormone receptors (TRs) are members of the nuclear hormone receptor superfamily. TRs might be interesting biomarkers - especially in the absence of classical hormone receptors. The current study aimed to investigate whether TRs may be specifically expressed in BRCA1 associated cancer cases and whether they are of prognostic significance in these patients as compared to sporadic breast cancer cases. This study analyzed TRα and TRβ immunopositivity in BRCA1 associated (n = 38) and sporadic breast cancer (n = 86). Further, TRs were studied in MCF7 (BRCA1 wildtype) and HCC3153 (BRCA1 mutated) cells. TRβ positivity rate was significantly higher in BRCA1 associated as compared to sporadic breast cancers (p = 0.001). The latter observation remained to be significant when cases that had been matched for clinicopathological criteria were compared (p = 0.037). Regarding BRCA1 associated breast cancer cases TRβ positivity turned out to be a positive prognostic factor for five-year (p = 0.007) and overall survival (p = 0.026) while TRα positivity predicted reduced five-year survival (p = 0.030). Activation of TRβ resulted in down-modulation of CTNNB1 while TRα inhibition reduced cell viability in HCC3153. However, only BRCA1 wildtype MCF7 cells were capable of rapidly degrading TRα1 in response to T3 stimulation. Significantly, this study identified TRβ to be up-regulated in BRCA1 associated breast cancer and revealed TRs to be associated with patients’ prognosis. TRs were also found to be expressed in triple negative BRCA1 associated breast cancer. Further studies need to be done in order to evaluate whether TRs may become interesting targets of endocrine therapeutic approaches, especially when tumors are triple-negative. Public Library of Science 2015-06-01 /pmc/articles/PMC4451081/ /pubmed/26029931 http://dx.doi.org/10.1371/journal.pone.0127072 Text en © 2015 Heublein et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Heublein, Sabine
Mayr, Doris
Meindl, Alfons
Angele, Martin
Gallwas, Julia
Jeschke, Udo
Ditsch, Nina
Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title_full Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title_fullStr Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title_full_unstemmed Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title_short Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways
title_sort thyroid hormone receptors predict prognosis in brca1 associated breast cancer in opposing ways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451081/
https://www.ncbi.nlm.nih.gov/pubmed/26029931
http://dx.doi.org/10.1371/journal.pone.0127072
work_keys_str_mv AT heubleinsabine thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT mayrdoris thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT meindlalfons thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT angelemartin thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT gallwasjulia thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT jeschkeudo thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways
AT ditschnina thyroidhormonereceptorspredictprognosisinbrca1associatedbreastcancerinopposingways